Figure 3 -.

Mouse to human studies using high dimensional analysis will drive the next generation of precision cancer immunotherapies. Single-cell and spatial technologies have the power to drive discoveries based on the cell types that are commonly affected by immunotherapies in preclinical and human tumors. Following identification of the commonalities between models, studies can focus on identifying molecular and cellular markers of response using multi-omics approaches. The combination of different layers of data will drive patient selection for the most adequate therapy, better clinical trial designs, and development of new immunotherapies.